Blinatumomab
- Generic Name
- Blinatumomab
- Brand Names
- Blincyto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 853426-35-4
- Unique Ingredient Identifier
- 4FR53SIF3A
- Background
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
- Indication
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
- Associated Conditions
- Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 83
- Registration Number
- NCT03109093
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Hessen, Germany
🇩🇪Charité - Campus Benjamin Franklin, Berlin, Germany
🇩🇪Uniklinik Dresden, Dresden, Germany
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 14
- Registration Number
- NCT03072771
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 47
- Registration Number
- NCT03023878
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT02961881
- Locations
- 🇦🇺
St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
🇩🇪Universitaetsklinikum Carl Gustav Carus, Dresden, Germany
🇮🇹IRCCS Ospedale San Raffaele, Milano, Italy
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02910063
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02879695
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideBiological: Inotuzumab OzogamicinOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateBiological: OfatumumabDrug: PrednisoneBiological: RituximabDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02877303
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT02811679
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02807883
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.